The dysfunctional endothelium in CKD and in cardiovascular disease: Mapping the origin(s) of cardiovascular problems in CKD and of kidney disease in cardiovascular conditions for a research agenda

Kidney International Supplements

Volumn 1, Issue 1, 2011, Pages 6-9

  Fliser, Danilo ^a   Wiecek, Andrzej ^b   Suleymanlar, Gultekin ^c   Ortiz, Alberto ^d   Massy, Ziad ^e,f   Lindholm, Bengt ^g   Martinez Castelao, Alberto ^h   Agarwal, Rajiv ⁱ   Jager, Kitty J ^j   Dekker, Friedo W ^k   Blankestijn, Peter J ^l   Goldsmith, David ^m   Covic, Adrian ⁿ   London, Gerard ^o   Zoccali, Carmine ^p  

^a SAARLAND UNIVERSITY   (Germany)

^b MEDICAL UNIVERSITY OF SILESIA   (Poland)

^c AKDENIZ UNIVERSITY   (Turkey)

^d UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^e INSERM   (France)

^f AMIENS UNIVERSITY HOSPITAL   (France)

^g KAROLINSKA INSTITUTE   (Sweden)

^h HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

ⁱ INDIANA UNIVERSITY   (United States)

^j UNIVERSITY OF AMSTERDAM   (Netherlands)

^k LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^l UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^m KING'S COLLEGE LONDON   (United Kingdom)

ⁿ C I PARHON NATIONAL INSTITUTE OF ENDOCRINOLOGY   (Romania)

^o PARIS CARDIOVASCULAR RESEARCH CENTER   (France)

^p CNR   (Italy)

more..

Author keywords

biomarkers; cardiovascular disease; chronic kidney disease; endothelium

Indexed keywords

EID: 84861510151     PISSN: 21571724     EISSN: 21571716     Source Type: Journal    
DOI: 10.1038/kisup.2011.6     Document Type: Review

References (10)

1. Aird WC. Phenotypic heterogeneity of the endothelium. I. Structure, function, and mechanisms. Circ Res 2007; 100: 158-173. (Pubitemid 46208717)
2. Aird WC. Phenotypic heterogeneity of the endothelium. II. Representative vascular beds. Circ Res 2007; 100: 173-190.
3. Tang EH, Vanhoutte PM. Endothelial dysfunction: a strategic target in the treatment of hypertension? Pflugers Arch 2010; 459: 995-1004.
4. Deanfield J, Donald A, Ferri C et al. Endothelial function and dysfunction. Part I: Methodological issues for assessment in the different vascular beds: a statement by the Working Group on Endothelin and Endothelial Factors of the European Society of Hypertension. J Hypertens 2005; 23: 7-17. (Pubitemid 40128972)
5. Brunner H, Cockcroft JR, Deanfield J et al. Endothelial function and dysfunction. Part II: Association with cardiovascular risk factors and diseases: a statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. J Hypertens 2005; 23: 233-246. (Pubitemid 40279622)
6. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685-1695.
7. Kang DK, Kanellis J, Hugo C et al. Role of the microvascular endothelium in progressive renal disease. J Am Soc Nephrol 2002; 13: 806-816. (Pubitemid 34183950)
8. Lerman A, Zeiher AM. Endothelial function: cardiac events. Circulation 2005; 111: 363-368. (Pubitemid 40165345)
9. Danesh J, Wheeler JG, Hirschfield GM et al. C-reactive protein and other markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004; 350: 1387-1397. (Pubitemid 38419992)
10. Ridker PM, Danielson E, Fonseca FA et al., Jupiter Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359: 2195-2207.